These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31746224)

  • 1. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
    Haunschild CE; Tewari KS
    Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
    Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
    In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
    Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
    Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
    Raouf S; Bertelli G; Ograbek A; Field P; Tran I
    Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
    N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.
    Wu X; Liu J; An R; Yin R; Zhang Y; Zhou H; He A; Wang L; Zhang J; Liu Z; Duan W; Zhu J; Lou G; Chen G; Cheng Y; Xue F; Nick S; Wang H; Li D
    J Gynecol Oncol; 2024 Sep; 35(5):e99. PubMed ID: 38872480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Retrospective Case Study of Combination Chemotherapy with Bevacizumab for Recurrent Ovarian Cancer].
    Hori K; Tsuruta T; Odani C; Ono H; Ohkubo R; Shimoji K; Murakami J; Nakagawa M; Tashima L; Ito K
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1197-1200. PubMed ID: 27760937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study.
    Xu Y; Xiong F; Li H; Zheng H; Jiang J; Li Q; Li G; Zhao W; Li R; Li J; Xie R; An R; Zhang H; Gao Q
    Int J Gynecol Cancer; 2024 Sep; 34(9):1461-1465. PubMed ID: 38658024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
    Zhang W; Shen Z; Luo H; Hu X; Zheng L; Zhu X
    Curr Drug Targets; 2017; 18(10):1125-1131. PubMed ID: 27138763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in Cervical Cancer: 5 Years After.
    Pfaendler KS; Liu MC; Tewari KS
    Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
    Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
    Shintani D; Yoshida H; Yabuno A; Fujiwara K
    In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
    Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
    Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.